Gln27→Gluβ2-adrenergic receptor polymorphism in heart failure patients: Differential clinical and oxidative response to carvedilol

Basic and Clinical Pharmacology and Toxicology

Volumn 104, Issue 5, 2009, Pages 374-378

  Troncoso, Rodrigo ^a   Moraga, Francisco ^a   Chiong, Mario ^a   Roldán, Juan ^a   Bravo, Roberto ^a   Valenzuela, Rodrigo ^a   Díaz Araya, Guillermo ^a   Del Campo, Andrea ^a   Sanhueza, Carlos ^a   Rodriguez, Andrea ^a   Vukasovic, José Luis ^b   Mellado, Rosemarie ^a,c   Greig, Douglas ^d   Castro, Pablo F ^d   Lavandero, Sergio ^a,b  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

^c Laboratory of Neurosciences   (Chile)

^d PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR; CARVEDILOL; GLUTAMIC ACID; GLUTAMINE; MALONALDEHYDE; NORADRENALIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG RESPONSE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MALE; NORADRENALIN BLOOD LEVEL; OXIDATION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; DOWN REGULATION; DRUG ANTAGONISM; GENETIC POLYMORPHISM; GENETICS; HEART LEFT VENTRICLE FUNCTION; METABOLISM; MIDDLE AGED; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PHARMACOGENETICS; PHYSIOLOGY;

ADRENERGIC BETA-ANTAGONISTS; CARBAZOLES; CHRONIC DISEASE; DOWN-REGULATION; FEMALE; HEART FAILURE; HUMANS; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROPANOLAMINES; RECEPTORS, ADRENERGIC, BETA-2; VENTRICULAR FUNCTION, LEFT;

EID: 64549105750     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2008.00370.x     Document Type: Article

References (28)

1. Brodde OE, Michel MC. Adrenergic and muscarinic receptors in the human heart. Pharmacol Rev 1999 51 : 651 90.
2. Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R et al. Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation 1990 82 : I12 25
3. Nabel EG. Cardiovascular disease. N Engl J Med 2003 349 : 60 72.
4. Insel PA. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med 1996 334 : 580 5.
5. Podlowski S, Wenzel K, Luther HP, Müller J, Bramlage P, Baumann G et al. Beta1-adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? J Mol Med 2000 78 : 87 93.
6. Liggett SB. Beta(2)-adrenergic receptor pharmacogenetics. Am J Respir Crit Care Med 2000 161 : S197 1.
7. Bristow MR, Gilbert EM, Abraham WT, Adams KF, Fowler MB, Hershberger RE et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996 94 : 2807 16.
8. Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M et al. Carvedilol Or Metoprolol European Trial Investigators. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol or Metoprolol European Trial (COMET): randomised controlled trial. Lancet 2003 362 : 7 13.
9. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996 334 : 1349 55.
10. Böhm M, Deutsch HJ, Hartmann D, Rosée KL, Stäblein A. Improvement of postreceptor events by metoprolol treatment in patients with chronic heart failure. J Am Coll Cardiol 1997 30 : 992 6.
11. Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA et al. Apoptosis in the failing human heart. N Engl J Med 1997 336 : 1131 41.
12. 2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997 100 : 3184 8.
13. Díaz-Vélez CR, García-Castiñeiras S, Mendoza-Ramos E, Hernández-López E. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996 131 : 146 52.
14. Lefkowitz RJ, Rockman HA, Koch WJ. Catecholamines, cardiac β-adrenergic receptors and heart failure. Circulation 2000 101 : 1634 7.
15. Eichhorn EJ. Prognosis determination in heart failure. Am J Med 2001 110 : 14S 36S.
16. Behonick GS, Novak MJ, Nealley EW, Baskin SI. Toxicology update: the cardiotoxicity of the oxidative stress metabolites of catecholamines (aminochromes). J Appl Toxicol 2001 21 : S15 22.
17. 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993 268 : 23116 21.
18. Small KM, Rathz DA, Liggett SB. Identification of adrenergic receptor polymorphisms. Methods Enzymol 2002 343 : 459 75.
19. 2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 2001 101 : 1707 14.
20. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001 345 : 1030 5.
21. Castro P, Vukasovic JL, Chiong M, Díaz-Araya G, Alcaino H, Copaja M et al. Effects of carvedilol on oxidative stress and chronotropic response to exercise in patients with chronic heart failure. Eur J Heart Fail 2005 7 : 1033 9.
22. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J 2005 26 : 943 5.
23. Palatini P, Julius S. Elevated heart rate: a major risk factor for cardiovascular disease. Clin Exp Hypertens 2004 26 : 637 44.
24. Vyssoulis GP, Marinakis AG, Aznaouridis KA, Karpanou EA, Arapogianni AN, Cokkinos DV et al. The impact of third-generation beta-blocker antihypertensive treatment on endothelial function and the prothrombotic state: effects of smoking. Am J Hypertens 2004 17 : 582 9.
25. Laufs U, Wassmann S, Schackmann S, Heeschen C, Böhm M, Nickenig G. Beneficial effects of statins in patients with non-ischemic heart failure. Z Kardiol 2004 93 : 103 8.
26. Castro PF, Mc-Nab P, Quintana JC, Bittner A, Greig D, Vergara I et al. Effects of carvedilol upon intra- and interventricular synchrony in patients with chronic heart failure. Am J Cardiol 2005 96 : 267 9.
27. Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz-Varley C, Ocampo ON et al. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999 90 : 2645 51.
28. Bernstein M, Tyagi SC. β-blocker improves cardiac function by reducing oxidative stress and metalloproteinase activity after myocardial infarction. J Appl Res 2001 1 : 149 51.